1 June 2026 in Nature Chemical Biology
Small, nonpolar cyclic peptides can both bind challenging targets and cross cell membranes, making them attractive for addressing currently undruggable targets such as many protein–protein interactions (PPIs). However, developing such compounds de novo without prior information about lead structures such as natural ligands or fragments remains a notable challenge. Here we show that functional screening of structurally highly diverse cyclic peptide libraries synthesized at nanomole scale allows identification of sub-kDa inhibitors of a PPI. By screening 15,360 fully random cyclic peptides, we were able to identify an inhibitor of the E3 ligase adaptor Keap1 and its substrate Nrf2. Optimization by rapid design–build–test cycles produced a membrane-permeable compound active in live cells. This study demonstrates that large, diverse cyclic peptide libraries can enable the discovery of cell-permeable PPI inhibitors from the ground up, providing a way to harness the powerful modality of small cyclic peptides to address often difficult-to-target intracellular interactions. The alternative text for this image may have been generated using AI.
9 September 2026 in bioRxiv
Candida auris ( C. auris ) is a rapidly emerging, multidrug-resistant fungal pathogen whose persistence is partly driven by adhesion to host tissues and abiotic surfaces. Surface-colonization factor 1 (Scf1) is a C. auris -specific adhesin implicated in surface adhesion, biofilm formation, virulence, and persistence in health care settings. However, the human proteins recognized by Scf1 and the response of these interactions to hydrodynamic flow and shear stress were previously unknown. Using yeast surface display, spinning-disk adhesion and FACS-based binding assays, we show that the N-terminal adhesive domain of Scf1 binds the cell-surface glycoprotein mucin-1 (MUC1) and the extracellular matrix proteins vitronectin (VIT) and fibronectin (FN), while exhibiting no detectable binding to collagen I, collagen IV, or fibrinogen. Hydrodynamic shear stress was found to tune ligand preference, with VIT being preferred at equilibrium and MUC1 being the more strongly bound target under flow. Epitope mapping by deep mutational scanning (DMS) of Scf1 against MUC1, VIT and FN identified shared binding patches consisting of predominantly cationic and aromatic residues involved in recognizing all three ligands. Mutations within these regions reduced binding without compromising yeast display expression levels, indicating that these residues are involved in ligand recognition and that mutations at these positions do not compromise global protein folding stability. These findings establish the Scf1 N-terminal domain as a semi-promiscuous ligand-recognition domain for a structurally diverse set of human proteins and suggest that a mechanosensitive adhesion mechanism contributes to C. auris colonization.
17 August 2024 in bioRxiv
Achieving high binding strength and efficient delivery of molecular cargo to tumor cells is a significant challenge in cancer immunotherapy. Current research has focused on obtaining antibodies that bind their targets with high affinity (i.e. low equilibrium dissociation constant, KD). However, such an approach neglects the influence of hydrodynamic fluid flow along the surfaces of cells and tissues, which can impart mechanical stress and lead to rapid unbinding of antibodies under flow. Here, we investigated how altering the anchor point within a non-antibody binding scaffold called Anticalin can enhance particle adhesion to the immune checkpoint CTLA-4 on human cells experiencing hydrodynamic shear. By introducing bioorthogonal clickable amino acids into Anticalin at various positions, we investigated the influence of different unbinding geometries on the stability of the Anticalin:(CTLA-4) complex. Both single-molecule AFM and quantitative bead-based adhesion assays on CTLA-4+ human cells demonstrate how optimal choice of the anchor point can stabilize the complex and enhance the adhesion strength of receptor-targeted particles. These results demonstrate how anchor point engineering can enhance particle adhesion and delivery to immunotherapy targets.